{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:14:56Z","timestamp":1790392496366,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,23]],"date-time":"2027-05-23T00:00:00Z","timestamp":1811030400000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000875","name":"The Pew Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008786","name":"Keck School of Medicine of USC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001353","name":"Alexander and Margaret Stewart Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cytogfr.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T22:57:54Z","timestamp":1779058674000},"page":"26-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cytokine-mediated intrinsic and extrinsic regulation of anti-tumor adoptive T cell therapy"],"prefix":"10.1016","volume":"90","author":[{"given":"Jing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5550-6701","authenticated-orcid":false,"given":"Bingfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.cytogfr.2026.05.002_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.05.002_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2026","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"48","key":"10.1016\/j.cytogfr.2026.05.002_bib6","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib7","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.05.002_bib8","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.05.002_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","article-title":"Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling","volume":"8","author":"Bell","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.05.002_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010672","article-title":"Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control","volume":"13","author":"Dysthe","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.05.002_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2026.05.002_bib14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fimmu.2019.01691","article-title":"An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2026.05.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115740","article-title":"Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment","volume":"168","author":"Zhou","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"16","key":"10.1016\/j.cytogfr.2026.05.002_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168706","article-title":"TGF-beta\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.05.002_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med"},{"issue":"6379","key":"10.1016\/j.cytogfr.2026.05.002_bib18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"625","key":"10.1016\/j.cytogfr.2026.05.002_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"625","key":"10.1016\/j.cytogfr.2026.05.002_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"ement 1","key":"10.1016\/j.cytogfr.2026.05.002_bib21","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood-2024-202090","article-title":"A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)","volume":"144","author":"Palomba","year":"2024","journal-title":"Blood"},{"issue":"8082","key":"10.1016\/j.cytogfr.2026.05.002_bib22","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41586-025-09393-1","article-title":"Expanding the cytokine receptor alphabet reprograms T cells into diverse states","volume":"645","author":"Zhao","year":"2025","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.05.002_bib23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib24","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.cytogfr.2026.05.002_bib25","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"issue":"6625","key":"10.1016\/j.cytogfr.2026.05.002_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib27","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/acssynbio.1c00236","article-title":"Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activation","volume":"11","author":"Guo","year":"2022","journal-title":"ACS Synth. Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib28","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41467-021-22980-w","article-title":"A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy","volume":"12","author":"Hsu","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.05.002_bib29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41422-021-00543-4","article-title":"Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res"},{"issue":"67","key":"10.1016\/j.cytogfr.2026.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib32","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.cytogfr.2026.05.002_bib33","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.05.002_bib34","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"526","key":"10.1016\/j.cytogfr.2026.05.002_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib36","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib37","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of CAR-T cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"17","key":"10.1016\/j.cytogfr.2026.05.002_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8075","article-title":"Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy","volume":"8","author":"Jones","year":"2022","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.cytogfr.2026.05.002_bib39","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2026.05.002_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1493257","article-title":"SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy","volume":"15","author":"Cini","year":"2024","journal-title":"Front Immunol."},{"issue":"36","key":"10.1016\/j.cytogfr.2026.05.002_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205983119","article-title":"Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies","volume":"119","author":"Lutz","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01508-3","article-title":"Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models","author":"Sasaki","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-023-01463-y","article-title":"Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8(+) T cells","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib44","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1038\/s41467-020-17011-z","article-title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy","volume":"11","author":"Evgin","year":"2020","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.cytogfr.2026.05.002_bib45","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1016\/j.cell.2022.11.016","article-title":"Engineered cell entry links receptor biology with single-cell genomics","volume":"185","author":"Yu","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41592-022-01436-z","article-title":"Antigen identification and high-throughput interaction mapping by reprogramming viral entry","volume":"19","author":"Dobson","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib47","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1038\/ncomms7246","article-title":"Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors","volume":"6","author":"Munch","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib48","doi-asserted-by":"crossref","DOI":"10.4110\/in.2026.26.e6","article-title":"Advances in IL-2 family cytokine-based cancer therapies: overcoming challenges through molecular engineering and delivery strategies","volume":"26","author":"An","year":"2026","journal-title":"Immune Netw."},{"key":"10.1016\/j.cytogfr.2026.05.002_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-026-01280-8","article-title":"Progress in the development of cytokine armoured CAR T cells","author":"Prasad","year":"2026","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ccell.2025.11.007","article-title":"IL-36gamma armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity","volume":"44","author":"Zuo","year":"2026","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.05.002_bib51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s12276-024-01249-4","article-title":"IL-33 and IL-33-derived DC-based tumor immunotherapy","volume":"56","author":"Kang","year":"2024","journal-title":"Exp. Mol. Med"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.05.002_bib53","article-title":"Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity","volume":"6","author":"Xiao","year":"2025","journal-title":"Cell Rep. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib54","doi-asserted-by":"crossref","DOI":"10.4110\/in.2026.26.e5","article-title":"Balancing intrinsic and extrinsic factors in CD8(+) T cell therapy","volume":"26","author":"Lee","year":"2026","journal-title":"Immune Netw."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","article-title":"Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy","volume":"75","author":"Zhang","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003633","article-title":"Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors","volume":"10","author":"Hu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01509-2","article-title":"Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery","author":"Murad","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"8034","key":"10.1016\/j.cytogfr.2026.05.002_bib58","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib59","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41590-023-01477-2","article-title":"Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells","volume":"24","author":"Corria-Osorio","year":"2023","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.05.002_bib60","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol. Res"},{"issue":"7637","key":"10.1016\/j.cytogfr.2026.05.002_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.05.002_bib62","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"7693","key":"10.1016\/j.cytogfr.2026.05.002_bib63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.cytogfr.2026.05.002_bib64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2026.05.002_bib66","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.05.002_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00262-026-04316-z","article-title":"CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity","volume":"75","author":"Adachi","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.05.002_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011382","article-title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","volume":"13","author":"de Sostoa","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"805","key":"10.1016\/j.cytogfr.2026.05.002_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado9511","article-title":"A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice","volume":"17","author":"Rossari","year":"2025","journal-title":"Sci. Transl. Med"},{"issue":"11-12","key":"10.1016\/j.cytogfr.2026.05.002_bib74","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/hum.2024.254","article-title":"Oncolytic adenovirus armoring with CXCL9 and IL15 shows potent antitumor activity and boosts CAR-T therapy for prostate cancer","volume":"36","author":"Fang","year":"2025","journal-title":"Hum. Gene Ther."},{"issue":"7918","key":"10.1016\/j.cytogfr.2026.05.002_bib75","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2025.10.021","article-title":"IL-9 signaling redirects CAR T cell fate toward CD8(+) memory and CD4(+) cycling states, enhancing antitumor efficacy","volume":"59","author":"Castelli","year":"2026","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.immuni.2025.10.024","article-title":"IL-9 as a naturally orthogonal cytokine with optimal JAK\/STAT signaling for engineered T cell therapy","volume":"59","author":"Jiang","year":"2026","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.05.002_bib78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","article-title":"c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation","volume":"4","author":"Xiong","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib79","doi-asserted-by":"crossref","unstructured":"W. Cho, J.Y. Liu, A.N. Beckett, J.C. Lunger, P. Xu, K. Ho, E.E. Chen, A. Salcido-Alc\u00e1ntar, L.E. Sant\u2019Anna, K. Obbad, N. Po, E. Sotillo, C.L. Mackall, K.G. Daniels, A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype, bioRxiv (2025) 2025.06.05.658149, https:\/\/doi.org\/10.1101\/2025.06.05.658149.","DOI":"10.1101\/2025.06.05.658149"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx9954","article-title":"Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics","author":"Rodriguez","year":"2026","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.05.002_bib81","article-title":"Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity","volume":"6","author":"Ahn","year":"2025","journal-title":"Cell Rep. Med"},{"issue":"7994","key":"10.1016\/j.cytogfr.2026.05.002_bib82","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib83","doi-asserted-by":"crossref","unstructured":"L. Oesinghaus, S. Becker, L. Vornholz, E. Papalexi, J. Pangallo, A.A. Moinfar, J. Liu, A.L. Fleur, M. Shulman, S. Marrujo, B. Hariadi, C. Curca, A. Suyama, M. Nigos, O. Sanderson, H. Nguyen, V.K. Tran, A.A. Sapre, O. Kaplan, S. Schroeder, A. Salvino, G. Gallareta-Olivares, R. Koehler, G. Geiss, A.B. Rosenberg, C.M. Roco, G. Seelig, F.J. Theis, A single-cell cytokine dictionary of human peripheral blood, bioRxiv (2025) 2025.12.12.693897, https:\/\/doi.org\/10.64898\/2025.12.12.693897.","DOI":"10.64898\/2025.12.12.693897"},{"issue":"25","key":"10.1016\/j.cytogfr.2026.05.002_bib84","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1016\/j.cell.2024.11.015","article-title":"How to build the virtual cell with artificial intelligence: priorities and opportunities","volume":"187","author":"Bunne","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib85","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","article-title":"CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics","volume":"20","author":"Jin","year":"2025","journal-title":"Nat. Protoc."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.05.002_bib86","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","article-title":"NicheNet: modeling intercellular communication by linking ligands to target genes","volume":"17","author":"Browaeys","year":"2020","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib88","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41592-022-01728-4","article-title":"Screening cell-cell communication in spatial transcriptomics via collective optimal transport","volume":"20","author":"Cang","year":"2023","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib89","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1038\/s41467-022-32111-8","article-title":"Knowledge-graph-based cell-cell communication inference for spatially resolved transcriptomic data with SpaTalk","volume":"13","author":"Shao","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.05.002_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13073-025-01518-5","article-title":"Cell-cell interactions as predictive and prognostic markers for drug responses in cancer","volume":"17","author":"Lu","year":"2025","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib91","article-title":"Mathematically mapping the network of cells in the tumor microenvironment","volume":"5","author":"van Santvoort","year":"2025","journal-title":"Cell Rep. Methods"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.05.002_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj0785","article-title":"Cell-cell communication network-based interpretable machine learning predicts cancer patient response to immune checkpoint inhibitors","volume":"10","author":"Lee","year":"2024","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.05.002_bib93","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.05.002_bib94","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ccell.2025.10.014","article-title":"A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma","volume":"44","author":"Rade","year":"2026","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.05.002_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004582","article-title":"Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade","volume":"10","author":"Harel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01633-7","article-title":"Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer","author":"Chen","year":"2026","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.05.002_bib97","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2026.05.002_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01594-3","article-title":"Lung tumouroids as a testing platform for precision CAR T cell therapy","author":"Ehlen","year":"2026","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.05.002_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:13:43Z","timestamp":1783635223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":99,"alternative-id":["S1359610126000407"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.05.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine-mediated intrinsic and extrinsic regulation of anti-tumor adoptive T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}